BioSpace News Archive

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 60,000 shares of its common stock to one new employee.

Acadia Pharmaceuticals Inc. announced that on October 4, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 145,119 shares of common stock and 38,559 restricted stock units to 19 new employees under Acadia’s 2023 Inducement Plan.

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.

InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for hard-to-treat solid tumors, is presenting preclinical data at 14th Annual World ADC Conference in San Diego regarding IN10018.

Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.

Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET.

Complete Genomics, Inc. announced its partnership with Integrated DNA Technologies, a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics’ innovative DNBSEQ™ sequencing platforms.

Novavax, Inc. today announced that Singapore’s Health Sciences Authority (HSA) has granted full approval for Novavax’s prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax, Inc. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.